Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2016.1215472 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intravitreal Sustained Release Steroid Implants Are Safe and Effective in Patients With Glaucoma Drainage Devices.
Retina
January 2025
Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.
Purpose: To describe effects of sustained-release steroid delivery devices on intraocular pressure (IOP) in eyes with glaucoma drainage devices (GDD).
Methods: Retrospective case series of eyes with steroid implants (dexamethasone or fluocinolone acetonide) and prior GDD (Ahmed, Baerveldt) without uveitis. Outcomes included IOP, IOP rise, central foveal thickness (CFT), and IOP medications.
Correction: Fluocinolone acetonide 0.2 µg/day intravitreal implant in non-infectious uveitis affecting the posterior segment: EU expert user panel consensus-based clinical recommendations.
J Ophthalmic Inflamm Infect
January 2025
Department of Ophthalmology, Pitié-Salpêtrière Hospital, Paris, France.
Injectable Intravitreal Fluocinolone Acetonide Implant for Chronic Postoperative CME in the Presence of Silicone Oil Tamponade.
Retin Cases Brief Rep
October 2024
Texas Retina Associates, Dallas, Texas.
Purpose: This report describes the use of the injectable intravitreal fluocinolone acetonide 0.18mg implant (FAI) for chronic postoperative cystoid macular edema (CME) in an eye with a silicone oil-filled vitreous cavity.
Methods: A retrospective chart review was performed including surgical, clinical, and imaging data.
Efficacy and Safety of Fluocinolone Acetonide 0.19 mg Intravitreal Implant for the Treatment of Non-Infectious Uveitis: A Systematic Review of Real-World Evidence.
Ocul Immunol Inflamm
December 2024
Department of Ophthalmology, Aalborg University Hospital, Aalborg, Denmark.
This systematic review evaluates the real-world efficacy and safety of the 0.19 mg fluocinolone acetonide (FAc) sustained-release intravitreal implant for treating non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). Following PRISMA guidelines, a search was conducted in PubMed, Embase and Web of Science, with the latest update on September 20, 2024.
View Article and Find Full Text PDFFluocinolone acetonide implant (FAci) one month after dexamethasone implant (DEXi) for chronic diabetic macular edema: 1-year results.
J Fr Ophtalmol
November 2024
Département d'Ophtalmologie, CHU d'Amiens Picardie, Amiens, France. Electronic address:
Purpose: To evaluate the safety and efficacy of FACi injected 1month after the last DEXi injection in pseudophakic patients without ocular hypertension who required frequent DEXi injections (<6months).
Patients And Methods: This was a prospective study including pseudophakic patients with chronic diabetic macular edema (DME) previously treated with DEXi without secondary ocular hypertension. All patients received DEXi followed by FAci one month later.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!